Form 4: Immunovant Director Andrew J. Fromkin Sells Shares to Cover Tax Obligations

Director Andrew J. Fromkin sold shares of Immunovant, Inc. common stock on March 7, 2025, to satisfy tax obligations related to the vesting of restricted stock units.

Summary

• Andrew J. Fromkin, a director of Immunovant, Inc., sold a total of 8,000 shares of common stock on March 7, 2025.
• The sales were executed in two transactions at weighted average prices of $19.52 and $19.96 per share.
• These transactions resulted in proceeds of approximately $156,000.
• Following the reported transactions, Fromkin beneficially owns 91,913 shares of Immunovant common stock.
• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 6, 2024, to cover tax obligations arising from the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock sales by a director under a pre-existing trading plan to cover tax obligations. There is no indication of positive or negative implications for the company.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider. It provides transparency to the market regarding the trading activities of individuals with access to non-public information.

Stakeholder Impact

• The stock sale may have a minor dilutive effect on existing shareholders.

Key Dates